Adaptive Biotech’s deal with Amgen influenced by belief that COVID-19 may return seasonally, like flu

Amgen plans to use Adaptive Biotech’s proprietary technology platform to develop therapies to treat the coronavirus, especially for those working on the frontlines treating patients.

READ THE ARTICLE at GeekWire »

PHOTO:  Pharmaceutical giant Amgen aims to develop a new drug to treat and prevent COVID-19, using insights from Seattle-based Adaptive Biotechnologies’ system for sequencing the human immune system. (Image Courtesy Adaptive Biotechnologies)